FocalTherics
FOCL Healthcare Medical Distribution
FocalTherics' revenue for fiscal 2025 (year ended December 2025) was $70.5 million, up 1.63% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS fell 129.4%, free cash flow grew 21.5% and total debt rose 366.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow FOCL
FocalTherics (FOCL) P/E ratio
FocalTherics has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,771× (May 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 248× | — |
| FY2020 | 0.0× | — |
| FY2019 | 84.7× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 20.9× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| SNYRQ Synergy CHC Corp. compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| HSIC Henry Schein, Inc. compare | 25.0× |
| CAH Cardinal Health, Inc. compare | 35.0× |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)